Even before Merck's public admission Thursday that Vioxx is harmful, hundreds of test cases were already headed to trial around the country. Now that Merck has pulled the plug on the drug, which netted $2.5 billion last year, plaintiffs attorneys are gearing up for a repeat of the Baycol, Rezulin and fen-phen torts, sending mass e-mails and issuing press releases to recruit Vioxx litigants. One attorney predicts the frenzy will "bring out the best and worst" in the legal profession.
News on Vioxx: A Shot in the Arm for Plaintiffs Bar
October 1, 2004
This article requires premium access
This article requires premium access to Law.com. Please sign in or subscribe to read the full text.